Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares fell 25% Monday after rival Novo Nordisk released positive data for its experimental sickle cell disease therapy.

This stands in contrast to the Phase 3 data from Agios (released in November) with its oral pyruvate kinase activator, ...

Novo Nordisk (NVO) stock rises, and Agios Pharma (AGIO) stock drops as the Danish company posts a late-stage trial win for a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novo Nordisk says it plans to apply for regulatory approval of its sickle cell disease, etavopivat, in the second half of ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's ...

Jackie Fouse is stepping down as CEO of Agios Pharmaceuticals, replaced by Brian Goff, a former executive with Alexion Pharmaceuticals, the company announced Tuesday. Fouse will remain with Agios as ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...

Agios Pharmaceuticals Inc. has agreed to sell its oncology business to Boston’s Servier Pharmaceuticals in a deal worth up to $2 billion. Agios, of Cambridge, which has two cancer drugs on the market ...